Skip to main content
Top
Published in: Translational Neurodegeneration 1/2014

Open Access 01-12-2014 | Review

Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology

Authors: Francisco Pan-Montojo, Heinz Reichmann

Published in: Translational Neurodegeneration | Issue 1/2014

Login to get access

Abstract

Neurodegenerative diseases are characterized by a progressive dysfunction of the nervous system. Often associated with atrophy of the affected central or peripheral nervous structures, they include diseases such as Parkinson’s Disease (PD), Alzheimer’s Disease and other dementias, Genetic Brain Disorders, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease), Huntington’s Disease, Prion Diseases, and others. The prevalence of neurodegenerative diseases has increased over the last years. This has had a major impact both on patients and their families and has exponentially increased the medical bill by hundreds of billions of Euros. Therefore, understanding the role of environmental and genetic factors in the pathogenesis of PD is crucial to develop preventive strategies. While some authors believe that PD is mainly genetic and that the aging of the society is the principal cause for this increase, different studies suggest that PD may be due to an increased exposure to environmental toxins. In this article we review epidemiological, sociological and experimental studies to determine which hypothesis is more plausible. Our conclusion is that, at least in idiopathic PD (iPD), the exposure to toxic environmental substances could play an important role in its aetiology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Checkoway H, Nelson LM: Epidemiologic approaches to the study of Parkinson’s disease etiology. Epidemiology 1999, 10: 327-336. 10.1097/00001648-199905000-00023PubMedCrossRef Checkoway H, Nelson LM: Epidemiologic approaches to the study of Parkinson’s disease etiology. Epidemiology 1999, 10: 327-336. 10.1097/00001648-199905000-00023PubMedCrossRef
2.
go back to reference Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003, 18: 19-31. 10.1002/mds.10305PubMedCrossRef Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003, 18: 19-31. 10.1002/mds.10305PubMedCrossRef
3.
go back to reference de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A: Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54: S21-S23.PubMed de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A: Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54: S21-S23.PubMed
4.
go back to reference Gasser T: Genetics of Parkinson’s disease. Clin Genet 1998, 54: 259-265. 10.1034/j.1399-0004.1998.5440401.xPubMedCrossRef Gasser T: Genetics of Parkinson’s disease. Clin Genet 1998, 54: 259-265. 10.1034/j.1399-0004.1998.5440401.xPubMedCrossRef
6.
go back to reference Ben-Shlomo Y: The epidemiology of Parkinson’s disease. Baillieres Clin Neurol 1997, 6: 55-68.PubMed Ben-Shlomo Y: The epidemiology of Parkinson’s disease. Baillieres Clin Neurol 1997, 6: 55-68.PubMed
7.
go back to reference Tanner CM, Ben-Shlomo Y: Epidemiology of Parkinson’s disease. Adv Neurol 1999, 80: 153-159.PubMed Tanner CM, Ben-Shlomo Y: Epidemiology of Parkinson’s disease. Adv Neurol 1999, 80: 153-159.PubMed
8.
go back to reference Kondo K: Rising prevalence of neurodegenerative diseases worldwide. Intern Med 1996, 35: 238. 10.2169/internalmedicine.35.238PubMedCrossRef Kondo K: Rising prevalence of neurodegenerative diseases worldwide. Intern Med 1996, 35: 238. 10.2169/internalmedicine.35.238PubMedCrossRef
9.
go back to reference Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, Dartigues JF, Brochard P: Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003, 22: 305-310. 10.1159/000071194PubMedCrossRef Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, Dartigues JF, Brochard P: Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003, 22: 305-310. 10.1159/000071194PubMedCrossRef
10.
go back to reference Freire C, Koifman S: Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology 2012, 33: 947-971. 10.1016/j.neuro.2012.05.011PubMedCrossRef Freire C, Koifman S: Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology 2012, 33: 947-971. 10.1016/j.neuro.2012.05.011PubMedCrossRef
11.
go back to reference Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ: The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50: 1346-1350. 10.1212/WNL.50.5.1346PubMedCrossRef Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ: The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50: 1346-1350. 10.1212/WNL.50.5.1346PubMedCrossRef
12.
go back to reference Gourie-Devi M, Ramu MG, Venkataram BS: Treatment of Parkinson’s disease in ‘Ayurveda’ (ancient Indian system of medicine): discussion paper. J R Soc Med 1991, 84: 491-492.PubMedCentralPubMed Gourie-Devi M, Ramu MG, Venkataram BS: Treatment of Parkinson’s disease in ‘Ayurveda’ (ancient Indian system of medicine): discussion paper. J R Soc Med 1991, 84: 491-492.PubMedCentralPubMed
13.
go back to reference Zhang ZX, Dong ZH, Roman GC: Early descriptions of Parkinson disease in ancient China. Arch Neurol 2006, 63: 782-784. 10.1001/archneur.63.5.782PubMedCrossRef Zhang ZX, Dong ZH, Roman GC: Early descriptions of Parkinson disease in ancient China. Arch Neurol 2006, 63: 782-784. 10.1001/archneur.63.5.782PubMedCrossRef
15.
go back to reference de Lau LM, Breteler MM: Epidemiology of Parkinson’s disease. Lancet Neurol 2006, 5: 525-535. 10.1016/S1474-4422(06)70471-9PubMedCrossRef de Lau LM, Breteler MM: Epidemiology of Parkinson’s disease. Lancet Neurol 2006, 5: 525-535. 10.1016/S1474-4422(06)70471-9PubMedCrossRef
16.
go back to reference Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E: Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 2012, 322: 254-262. 10.1016/j.jns.2012.05.030PubMedCrossRef Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E: Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 2012, 322: 254-262. 10.1016/j.jns.2012.05.030PubMedCrossRef
17.
go back to reference Wilmoth JR: Methods protocol for the human mortality database. Book Methods Protocol for the Human Mortality Database 2002. (Editor ed.^eds.). City Wilmoth JR: Methods protocol for the human mortality database. Book Methods Protocol for the Human Mortality Database 2002. (Editor ed.^eds.). City
18.
go back to reference Goerlich Gisbert FJAPP: Esperanza de vida en España a lo largo del siglo XX. BBVA 2006, 1: 5-43. Goerlich Gisbert FJAPP: Esperanza de vida en España a lo largo del siglo XX. BBVA 2006, 1: 5-43.
19.
go back to reference Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, Sandler D: Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol 2007, 165: 364-374.PubMedCrossRef Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, Sandler D: Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol 2007, 165: 364-374.PubMedCrossRef
20.
go back to reference Ranga Rao GV RO, Rameshwar Rao V, Reddy YVR: Role of biopesticides in crop protection: present status and future prospects. Indian J Plant Prot 2007, 35: 1-9. Ranga Rao GV RO, Rameshwar Rao V, Reddy YVR: Role of biopesticides in crop protection: present status and future prospects. Indian J Plant Prot 2007, 35: 1-9.
21.
go back to reference Metcalf RL: Organic Insecticides: Their Chemistry and Mode of Action. New York: Interscience Publishers, Inc.; 1955. Metcalf RL: Organic Insecticides: Their Chemistry and Mode of Action. New York: Interscience Publishers, Inc.; 1955.
22.
go back to reference Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC: Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 1997, 48: 1583-1588. 10.1212/WNL.48.6.1583PubMedCrossRef Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC: Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 1997, 48: 1583-1588. 10.1212/WNL.48.6.1583PubMedCrossRef
23.
go back to reference Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS: Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res 2001, 86: 122-127. 10.1006/enrs.2001.4264PubMedCrossRef Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS: Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res 2001, 86: 122-127. 10.1006/enrs.2001.4264PubMedCrossRef
24.
go back to reference Lai BC, Marion SA, Teschke K, Tsui JK: Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 2002, 8: 297-309. 10.1016/S1353-8020(01)00054-2PubMedCrossRef Lai BC, Marion SA, Teschke K, Tsui JK: Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 2002, 8: 297-309. 10.1016/S1353-8020(01)00054-2PubMedCrossRef
25.
go back to reference Rajput AH, Uitti RJ, Stern W, Laverty W: Early onset Parkinson’s disease in Saskatchewan–environmental considerations for etiology. Can J Neurol Sci 1986, 13: 312-316.PubMed Rajput AH, Uitti RJ, Stern W, Laverty W: Early onset Parkinson’s disease in Saskatchewan–environmental considerations for etiology. Can J Neurol Sci 1986, 13: 312-316.PubMed
26.
go back to reference Behari M, Srivastava AK, Das RR, Pandey RM: Risk factors of Parkinson’s disease in Indian patients. J Neurol Sci 2001, 190: 49-55. 10.1016/S0022-510X(01)00578-0PubMedCrossRef Behari M, Srivastava AK, Das RR, Pandey RM: Risk factors of Parkinson’s disease in Indian patients. J Neurol Sci 2001, 190: 49-55. 10.1016/S0022-510X(01)00578-0PubMedCrossRef
27.
go back to reference Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E: Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 1996, 46: 1275-1284. 10.1212/WNL.46.5.1275PubMedCrossRef Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E: Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 1996, 46: 1275-1284. 10.1212/WNL.46.5.1275PubMedCrossRef
28.
go back to reference Semchuk KM, Love EJ, Lee RG: Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42: 1328-1335. 10.1212/WNL.42.7.1328PubMedCrossRef Semchuk KM, Love EJ, Lee RG: Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42: 1328-1335. 10.1212/WNL.42.7.1328PubMedCrossRef
29.
go back to reference Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR: Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol 1994, 36: 100-103. 10.1002/ana.410360119PubMedCrossRef Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR: Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol 1994, 36: 100-103. 10.1002/ana.410360119PubMedCrossRef
30.
go back to reference Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW: Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 2011, 119: 866-872. 10.1289/ehp.1002839PubMedCentralPubMedCrossRef Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW: Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 2011, 119: 866-872. 10.1289/ehp.1002839PubMedCentralPubMedCrossRef
31.
go back to reference Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, Guerineau V, Laprevote O, Medja F, Lombes A, Michel PP, Lannuzel A, Hirsch EC, Ruberg M: Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004, 88: 63-69.PubMedCrossRef Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, Guerineau V, Laprevote O, Medja F, Lombes A, Michel PP, Lannuzel A, Hirsch EC, Ruberg M: Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004, 88: 63-69.PubMedCrossRef
32.
go back to reference Huang CC, Lu CS, Chu NS, Hochberg F, Lilienfeld D, Olanow W, Calne DB: Progression after chronic manganese exposure. Neurology 1993, 43: 1479-1483. 10.1212/WNL.43.8.1479PubMedCrossRef Huang CC, Lu CS, Chu NS, Hochberg F, Lilienfeld D, Olanow W, Calne DB: Progression after chronic manganese exposure. Neurology 1993, 43: 1479-1483. 10.1212/WNL.43.8.1479PubMedCrossRef
33.
go back to reference Needleman H, Landrigan PJ: Toxins at the pump. New York Times 1996, 15. Needleman H, Landrigan PJ: Toxins at the pump. New York Times 1996, 15.
34.
go back to reference Richardson JR, Roy A, Shalat SL, Buckley B, Winnik B, Gearing M, Levey AI, Factor SA, O’Suilleabhain P, German DC: Beta-hexachlorocyclohexane levels in serum and risk of Parkinson’s disease. Neurotoxicology 2011, 32: 640-645. 10.1016/j.neuro.2011.04.002PubMedCentralPubMedCrossRef Richardson JR, Roy A, Shalat SL, Buckley B, Winnik B, Gearing M, Levey AI, Factor SA, O’Suilleabhain P, German DC: Beta-hexachlorocyclohexane levels in serum and risk of Parkinson’s disease. Neurotoxicology 2011, 32: 640-645. 10.1016/j.neuro.2011.04.002PubMedCentralPubMedCrossRef
35.
go back to reference Brownson DM, Mabry TJ, Leslie SW: The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol 2002, 82: 159-167. 10.1016/S0378-8741(02)00170-8PubMedCrossRef Brownson DM, Mabry TJ, Leslie SW: The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol 2002, 82: 159-167. 10.1016/S0378-8741(02)00170-8PubMedCrossRef
36.
go back to reference Seawright AA: Directly toxic effects of plant chemicals which may occur in human and animal foods. Nat Toxins 1995, 3: 227-232. discussion 242 10.1002/nt.2620030411PubMedCrossRef Seawright AA: Directly toxic effects of plant chemicals which may occur in human and animal foods. Nat Toxins 1995, 3: 227-232. discussion 242 10.1002/nt.2620030411PubMedCrossRef
37.
go back to reference Bradley WG, Mash DC: Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler 2009, 10(Suppl 2):7-20.PubMedCrossRef Bradley WG, Mash DC: Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler 2009, 10(Suppl 2):7-20.PubMedCrossRef
38.
go back to reference Kurland LT, Mulder DW: Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution and special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954, 4: 438-448. 10.1212/WNL.4.6.438PubMedCrossRef Kurland LT, Mulder DW: Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution and special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954, 4: 438-448. 10.1212/WNL.4.6.438PubMedCrossRef
39.
go back to reference Plato CC, Garruto RM, Galasko D, Craig UK, Plato M, Gamst A, Torres JM, Wiederholt W: Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 2003, 157: 149-157. 10.1093/aje/kwf175PubMedCrossRef Plato CC, Garruto RM, Galasko D, Craig UK, Plato M, Gamst A, Torres JM, Wiederholt W: Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 2003, 157: 149-157. 10.1093/aje/kwf175PubMedCrossRef
40.
go back to reference Doder M, Jahanshahi M, Turjanski N, Moseley IF, Lees AJ: Parkinson’s syndrome after closed head injury: a single case report. J Neurol Neurosurg Psychiatry 1999, 66: 380-385. 10.1136/jnnp.66.3.380PubMedCentralPubMedCrossRef Doder M, Jahanshahi M, Turjanski N, Moseley IF, Lees AJ: Parkinson’s syndrome after closed head injury: a single case report. J Neurol Neurosurg Psychiatry 1999, 66: 380-385. 10.1136/jnnp.66.3.380PubMedCentralPubMedCrossRef
41.
go back to reference Nayernouri T: Posttraumatic parkinsonism. Surg Neurol 1985, 24: 263-264. 10.1016/0090-3019(85)90035-7PubMedCrossRef Nayernouri T: Posttraumatic parkinsonism. Surg Neurol 1985, 24: 263-264. 10.1016/0090-3019(85)90035-7PubMedCrossRef
42.
go back to reference Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW: Head injury and Parkinson’s disease risk in twins. Ann Neurol 2006, 60: 65-72. 10.1002/ana.20882PubMedCrossRef Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW: Head injury and Parkinson’s disease risk in twins. Ann Neurol 2006, 60: 65-72. 10.1002/ana.20882PubMedCrossRef
43.
go back to reference Jafari S, Etminan M, Aminzadeh F, Samii A: Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord 2013, 28: 1222-1229. 10.1002/mds.25458PubMedCrossRef Jafari S, Etminan M, Aminzadeh F, Samii A: Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord 2013, 28: 1222-1229. 10.1002/mds.25458PubMedCrossRef
44.
go back to reference Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304: 1-7. 10.1124/jpet.102.035048PubMedCrossRef Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304: 1-7. 10.1124/jpet.102.035048PubMedCrossRef
45.
go back to reference Ghaemi M, Rudolf J, Schmulling S, Bamborschke S, Heiss WD: FDG- and Dopa-PET in postencephalitic parkinsonism. J Neural Transm 2000, 107: 1289-1295. 10.1007/s007020070018PubMedCrossRef Ghaemi M, Rudolf J, Schmulling S, Bamborschke S, Heiss WD: FDG- and Dopa-PET in postencephalitic parkinsonism. J Neural Transm 2000, 107: 1289-1295. 10.1007/s007020070018PubMedCrossRef
46.
go back to reference Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57: 456-462. 10.1212/WNL.57.3.456PubMedCrossRef Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57: 456-462. 10.1212/WNL.57.3.456PubMedCrossRef
47.
go back to reference Selby G: The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson’s disease. Clin Exp Neurol 1984, 20: 1-25.PubMed Selby G: The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson’s disease. Clin Exp Neurol 1984, 20: 1-25.PubMed
48.
go back to reference Baron JA: Cigarette smoking and Parkinson’s disease. Neurology 1986, 36: 1490-1496. 10.1212/WNL.36.11.1490PubMedCrossRef Baron JA: Cigarette smoking and Parkinson’s disease. Neurology 1986, 36: 1490-1496. 10.1212/WNL.36.11.1490PubMedCrossRef
49.
go back to reference Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC: Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001, 50: 56-63. 10.1002/ana.1052PubMedCrossRef Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC: Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001, 50: 56-63. 10.1002/ana.1052PubMedCrossRef
50.
go back to reference Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007, 166: 561-567. 10.1093/aje/kwm127PubMedCentralPubMedCrossRef Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007, 166: 561-567. 10.1093/aje/kwm127PubMedCentralPubMedCrossRef
51.
go back to reference Forno LS: Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996, 55: 259-272. 10.1097/00005072-199603000-00001PubMedCrossRef Forno LS: Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996, 55: 259-272. 10.1097/00005072-199603000-00001PubMedCrossRef
52.
go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839-840. 10.1038/42166PubMedCrossRef Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839-840. 10.1038/42166PubMedCrossRef
53.
go back to reference Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24: 197-211. 10.1016/S0197-4580(02)00065-9PubMedCrossRef Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24: 197-211. 10.1016/S0197-4580(02)00065-9PubMedCrossRef
54.
go back to reference Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K: Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004, 318: 121-134. 10.1007/s00441-004-0956-9PubMedCrossRef Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K: Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004, 318: 121-134. 10.1007/s00441-004-0956-9PubMedCrossRef
55.
go back to reference Wakabayashi K, Takahashi H: Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 1997, 38(Suppl 2):2-7.PubMedCrossRef Wakabayashi K, Takahashi H: Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 1997, 38(Suppl 2):2-7.PubMedCrossRef
56.
go back to reference Braak H, de Vos RA, Bohl J, Del Tredici K: Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006, 396: 67-72. 10.1016/j.neulet.2005.11.012PubMedCrossRef Braak H, de Vos RA, Bohl J, Del Tredici K: Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006, 396: 67-72. 10.1016/j.neulet.2005.11.012PubMedCrossRef
57.
go back to reference Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H: Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010, 119: 703-713. 10.1007/s00401-010-0665-2PubMedCrossRef Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H: Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010, 119: 703-713. 10.1007/s00401-010-0665-2PubMedCrossRef
58.
go back to reference Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H: Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005, 109: 583-588. 10.1007/s00401-005-0995-7PubMedCrossRef Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H: Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005, 109: 583-588. 10.1007/s00401-005-0995-7PubMedCrossRef
59.
go back to reference Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 2001, 16: 507-510. 10.1002/mds.1099PubMedCrossRef Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 2001, 16: 507-510. 10.1002/mds.1099PubMedCrossRef
60.
go back to reference Chaudhuri KR, Martinez-Martin P: Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008, 15(Suppl 2):2-7.PubMedCrossRef Chaudhuri KR, Martinez-Martin P: Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008, 15(Suppl 2):2-7.PubMedCrossRef
61.
go back to reference Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H: Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 2007, 22: 839-842. 10.1002/mds.21413PubMedCrossRef Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H: Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 2007, 22: 839-842. 10.1002/mds.21413PubMedCrossRef
62.
go back to reference Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H: Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004, 19: 1196-1202. 10.1002/mds.20141PubMedCrossRef Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H: Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004, 19: 1196-1202. 10.1002/mds.20141PubMedCrossRef
63.
go back to reference Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW: Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry 2010, 81: 396-399. 10.1136/jnnp.2009.183715PubMedCrossRef Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW: Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry 2010, 81: 396-399. 10.1136/jnnp.2009.183715PubMedCrossRef
64.
go back to reference Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G: Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain: a j neurol 2005, 128: 126-137.CrossRef Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G: Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain: a j neurol 2005, 128: 126-137.CrossRef
65.
go back to reference Gowers W: Diseases of the nervous system. London: Chapman; 1888. Gowers W: Diseases of the nervous system. London: Chapman; 1888.
66.
go back to reference Payami H, Larsen K, Bernard S, Nutt J: Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol 1994, 36: 659-661. 10.1002/ana.410360417PubMedCrossRef Payami H, Larsen K, Bernard S, Nutt J: Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol 1994, 36: 659-661. 10.1002/ana.410360417PubMedCrossRef
67.
go back to reference Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G: Familial Parkinson’s disease: a clinical genetic analysis. Can J Neurol Sci 1995, 22: 272-279.PubMedCrossRef Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G: Familial Parkinson’s disease: a clinical genetic analysis. Can J Neurol Sci 1995, 22: 272-279.PubMedCrossRef
68.
go back to reference Vieregge P, Heberlein I: Increased risk of Parkinson’s disease in relatives of patients. Ann Neurol 1995, 37: 685.PubMedCrossRef Vieregge P, Heberlein I: Increased risk of Parkinson’s disease in relatives of patients. Ann Neurol 1995, 37: 685.PubMedCrossRef
69.
go back to reference De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, Marconi R, Castellano AE, Campanella G: Environmental and genetic risk factors in Parkinson’s disease: a case-control study in southern Italy. Mov Disord 1996, 11: 17-23. 10.1002/mds.870110105PubMedCrossRef De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, Marconi R, Castellano AE, Campanella G: Environmental and genetic risk factors in Parkinson’s disease: a case-control study in southern Italy. Mov Disord 1996, 11: 17-23. 10.1002/mds.870110105PubMedCrossRef
70.
go back to reference Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R: Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology 1996, 47: 155-160. 10.1212/WNL.47.1.155PubMedCrossRef Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R: Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology 1996, 47: 155-160. 10.1212/WNL.47.1.155PubMedCrossRef
71.
go back to reference Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW: Parkinson disease in twins: an etiologic study. JAMA 1999, 281: 341-346. 10.1001/jama.281.4.341PubMedCrossRef Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW: Parkinson disease in twins: an etiologic study. JAMA 1999, 281: 341-346. 10.1001/jama.281.4.341PubMedCrossRef
72.
go back to reference Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276: 2045-2047. 10.1126/science.276.5321.2045PubMedCrossRef Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276: 2045-2047. 10.1126/science.276.5321.2045PubMedCrossRef
73.
go back to reference Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: Alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003, 302: 841. 10.1126/science.1090278PubMedCrossRef Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: Alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003, 302: 841. 10.1126/science.1090278PubMedCrossRef
74.
go back to reference Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392: 605-608. 10.1038/33416PubMedCrossRef Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392: 605-608. 10.1038/33416PubMedCrossRef
75.
go back to reference Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH: Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson’s disease. Hum Genet 1998, 103: 424-427. 10.1007/s004390050845PubMedCrossRef Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH: Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson’s disease. Hum Genet 1998, 103: 424-427. 10.1007/s004390050845PubMedCrossRef
76.
go back to reference Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR: PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004, 56: 336-341. 10.1002/ana.20256PubMedCrossRef Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR: PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004, 56: 336-341. 10.1002/ana.20256PubMedCrossRef
77.
go back to reference Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T: Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 2005, 365: 410-412.PubMed Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T: Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 2005, 365: 410-412.PubMed
78.
go back to reference Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K, Sveinbjornsdottir S: A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol 2002, 52: 549-555. 10.1002/ana.10324PubMedCrossRef Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K, Sveinbjornsdottir S: A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol 2002, 52: 549-555. 10.1002/ana.10324PubMedCrossRef
79.
go back to reference Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T: Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003, 72: 1053-1057. 10.1086/374383PubMedCentralPubMedCrossRef Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T: Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003, 72: 1053-1057. 10.1086/374383PubMedCentralPubMedCrossRef
80.
go back to reference Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schols L, Schulz JB, Riess O, Kruger R: Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet 2003, 12: 1223-1231. 10.1093/hmg/ddg134PubMedCrossRef Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schols L, Schulz JB, Riess O, Kruger R: Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet 2003, 12: 1223-1231. 10.1093/hmg/ddg134PubMedCrossRef
81.
go back to reference Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK: Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003, 33: 85-89.PubMedCrossRef Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK: Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003, 33: 85-89.PubMedCrossRef
82.
go back to reference Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez De Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB: Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004, 44: 595-600. 10.1016/j.neuron.2004.10.023PubMedCrossRef Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez De Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB: Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004, 44: 595-600. 10.1016/j.neuron.2004.10.023PubMedCrossRef
83.
go back to reference Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, et al.: Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet 2012, 8: e1002548. 10.1371/journal.pgen.1002548PubMedCentralPubMedCrossRef Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, et al.: Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet 2012, 8: e1002548. 10.1371/journal.pgen.1002548PubMedCentralPubMedCrossRef
84.
go back to reference Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005, 28: 57-87. 10.1146/annurev.neuro.28.061604.135718PubMedCrossRef Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005, 28: 57-87. 10.1146/annurev.neuro.28.061604.135718PubMedCrossRef
86.
go back to reference Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, Haass C: Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. Embo J 2010, 29: 3571-3589. 10.1038/emboj.2010.223PubMedCentralPubMedCrossRef Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, Haass C: Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. Embo J 2010, 29: 3571-3589. 10.1038/emboj.2010.223PubMedCentralPubMedCrossRef
87.
go back to reference Feany MB, Bender WW: A Drosophila model of Parkinson’s disease. Nature 2000, 404: 394-398. 10.1038/35006074PubMedCrossRef Feany MB, Bender WW: A Drosophila model of Parkinson’s disease. Nature 2000, 404: 394-398. 10.1038/35006074PubMedCrossRef
88.
go back to reference Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O: Zebrafish as a new animal model for movement disorders. J Neurochem 2008, 106: 1991-1997. 10.1111/j.1471-4159.2008.05463.xPubMedCrossRef Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O: Zebrafish as a new animal model for movement disorders. J Neurochem 2008, 106: 1991-1997. 10.1111/j.1471-4159.2008.05463.xPubMedCrossRef
89.
go back to reference Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441: 1162-1166. 10.1038/nature04779PubMedCrossRef Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441: 1162-1166. 10.1038/nature04779PubMedCrossRef
90.
go back to reference da Costa CA, Ancolio K, Checler F: Wild-type but not Parkinson’s disease-related ala-53 Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. The J biol chem 2000, 275: 24065-24069. 10.1074/jbc.M002413200PubMedCrossRef da Costa CA, Ancolio K, Checler F: Wild-type but not Parkinson’s disease-related ala-53 Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. The J biol chem 2000, 275: 24065-24069. 10.1074/jbc.M002413200PubMedCrossRef
91.
go back to reference Leng Y, Chuang DM: Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006, 26: 7502-7512. 10.1523/JNEUROSCI.0096-06.2006PubMedCrossRef Leng Y, Chuang DM: Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006, 26: 7502-7512. 10.1523/JNEUROSCI.0096-06.2006PubMedCrossRef
92.
go back to reference Yadav S, Dixit A, Agrawal S, Singh A, Srivastava G, Singh AK, Srivastava PK, Prakash O, Singh MP: Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson’s disease pathogenesis. Mol Neurobiol 2012, 46: 495-512. 10.1007/s12035-012-8291-8PubMedCrossRef Yadav S, Dixit A, Agrawal S, Singh A, Srivastava G, Singh AK, Srivastava PK, Prakash O, Singh MP: Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson’s disease pathogenesis. Mol Neurobiol 2012, 46: 495-512. 10.1007/s12035-012-8291-8PubMedCrossRef
93.
94.
go back to reference Blandini F, Armentero MT: Animal models of Parkinson’s disease. Febs J 2012, 279: 1156-1166. 10.1111/j.1742-4658.2012.08491.xPubMedCrossRef Blandini F, Armentero MT: Animal models of Parkinson’s disease. Febs J 2012, 279: 1156-1166. 10.1111/j.1742-4658.2012.08491.xPubMedCrossRef
95.
go back to reference Langston JW, Ballard PA Jr: Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983, 309: 310.PubMed Langston JW, Ballard PA Jr: Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983, 309: 310.PubMed
96.
go back to reference Wright JM, Wall RA, Perry TL, Paty DW: Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. N Engl J Med 1984, 310: 325.PubMed Wright JM, Wall RA, Perry TL, Paty DW: Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. N Engl J Med 1984, 310: 325.PubMed
97.
go back to reference Boatell ML, Mahy N, Cardozo A, Ambrosio S, Tolosa E, Cruz-Sanchez FF: Neuronal changes in the nigrostriatal pathway of 1-methyl-4-phenylpyridine-treated mice. Methods Find Exp Clin Pharmacol 1992, 14: 781-787.PubMed Boatell ML, Mahy N, Cardozo A, Ambrosio S, Tolosa E, Cruz-Sanchez FF: Neuronal changes in the nigrostriatal pathway of 1-methyl-4-phenylpyridine-treated mice. Methods Find Exp Clin Pharmacol 1992, 14: 781-787.PubMed
98.
go back to reference Hoeglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7: 726-735. 10.1038/nn1265CrossRef Hoeglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7: 726-735. 10.1038/nn1265CrossRef
99.
100.
go back to reference Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM: Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease. Brain Res Mol Brain Res 2005, 134: 103-108. 10.1016/j.molbrainres.2005.01.012PubMedCrossRef Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM: Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease. Brain Res Mol Brain Res 2005, 134: 103-108. 10.1016/j.molbrainres.2005.01.012PubMedCrossRef
101.
go back to reference Ungerstedt U, Ljungberg T, Steg G: Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 1974, 5: 421-426.PubMed Ungerstedt U, Ljungberg T, Steg G: Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 1974, 5: 421-426.PubMed
102.
go back to reference Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24: 485-493. 10.1016/0006-8993(70)90187-3PubMedCrossRef Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24: 485-493. 10.1016/0006-8993(70)90187-3PubMedCrossRef
103.
go back to reference Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA: The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002, 277: 1641-1644. 10.1074/jbc.C100560200PubMedCrossRef Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA: The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002, 277: 1641-1644. 10.1074/jbc.C100560200PubMedCrossRef
104.
go back to reference Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000, 3: 1301-1306. 10.1038/81834PubMedCrossRef Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000, 3: 1301-1306. 10.1038/81834PubMedCrossRef
105.
go back to reference Alam M, Schmidt WJ: Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136: 317-324. 10.1016/S0166-4328(02)00180-8PubMedCrossRef Alam M, Schmidt WJ: Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136: 317-324. 10.1016/S0166-4328(02)00180-8PubMedCrossRef
106.
go back to reference Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT: Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 2003, 23: 10756-10764.PubMed Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT: Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 2003, 23: 10756-10764.PubMed
107.
go back to reference Di Monte DA: The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003, 2: 531-538. 10.1016/S1474-4422(03)00501-5PubMedCrossRef Di Monte DA: The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003, 2: 531-538. 10.1016/S1474-4422(03)00501-5PubMedCrossRef
108.
go back to reference Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S: Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007, 101: 1491-1504. 10.1111/j.1471-4159.2006.04440.xPubMedCrossRef Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S: Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007, 101: 1491-1504. 10.1111/j.1471-4159.2006.04440.xPubMedCrossRef
109.
go back to reference Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH: Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5: e8762. 10.1371/journal.pone.0008762PubMedCentralPubMedCrossRef Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH: Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5: e8762. 10.1371/journal.pone.0008762PubMedCentralPubMedCrossRef
110.
go back to reference Ferrante RJ, Schulz JB, Kowall NW, Beal MF: Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997, 753: 157-162. 10.1016/S0006-8993(97)00008-5PubMedCrossRef Ferrante RJ, Schulz JB, Kowall NW, Beal MF: Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997, 753: 157-162. 10.1016/S0006-8993(97)00008-5PubMedCrossRef
111.
go back to reference Hoeglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC: Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003, 84: 491-502. 10.1046/j.1471-4159.2003.01533.xCrossRef Hoeglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC: Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003, 84: 491-502. 10.1046/j.1471-4159.2003.01533.xCrossRef
112.
go back to reference Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H: Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Reports 2012, 2: 898. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H: Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Reports 2012, 2: 898.
113.
go back to reference Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, et al.: Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica 2013, 125: 795-813. 10.1007/s00401-013-1114-9PubMedCentralPubMedCrossRef Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, et al.: Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica 2013, 125: 795-813. 10.1007/s00401-013-1114-9PubMedCentralPubMedCrossRef
114.
go back to reference Uversky VN, Li J, Fink AL: Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001, 500: 105-108. 10.1016/S0014-5793(01)02597-2PubMedCrossRef Uversky VN, Li J, Fink AL: Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001, 500: 105-108. 10.1016/S0014-5793(01)02597-2PubMedCrossRef
115.
go back to reference Uversky VN, Li J, Fink AL: Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem 2001, 276: 44284-44296. 10.1074/jbc.M105343200PubMedCrossRef Uversky VN, Li J, Fink AL: Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem 2001, 276: 44284-44296. 10.1074/jbc.M105343200PubMedCrossRef
116.
go back to reference Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM: Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. J Biol Chem 2008, 283: 34696-34703. 10.1074/jbc.M802210200PubMedCentralPubMedCrossRef Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM: Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. J Biol Chem 2008, 283: 34696-34703. 10.1074/jbc.M802210200PubMedCentralPubMedCrossRef
117.
go back to reference Giordano G, Afsharinejad Z, Guizzetti M, Vitalone A, Kavanagh TJ, Costa LG: Organophosphorus insecticides chlorpyrifos and diazinon and oxidative stress in neuronal cells in a genetic model of glutathione deficiency. Toxicol Appl Pharmacol 2007, 219: 181-189. 10.1016/j.taap.2006.09.016PubMedCrossRef Giordano G, Afsharinejad Z, Guizzetti M, Vitalone A, Kavanagh TJ, Costa LG: Organophosphorus insecticides chlorpyrifos and diazinon and oxidative stress in neuronal cells in a genetic model of glutathione deficiency. Toxicol Appl Pharmacol 2007, 219: 181-189. 10.1016/j.taap.2006.09.016PubMedCrossRef
118.
go back to reference Schuh RA, Kristian T, Gupta RK, Flaws JA, Fiskum G: Methoxychlor inhibits brain mitochondrial respiration and increases hydrogen peroxide production and CREB phosphorylation. Toxicol Sci 2005, 88: 495-504. 10.1093/toxsci/kfi334PubMedCrossRef Schuh RA, Kristian T, Gupta RK, Flaws JA, Fiskum G: Methoxychlor inhibits brain mitochondrial respiration and increases hydrogen peroxide production and CREB phosphorylation. Toxicol Sci 2005, 88: 495-504. 10.1093/toxsci/kfi334PubMedCrossRef
119.
go back to reference Jenkins SM, Barone S: The neurotoxicant trimethyltin induces apoptosis via caspase activation, p38 protein kinase, and oxidative stress in PC12 cells. Toxicol Lett 2004, 147: 63-72. 10.1016/j.toxlet.2003.10.023PubMedCrossRef Jenkins SM, Barone S: The neurotoxicant trimethyltin induces apoptosis via caspase activation, p38 protein kinase, and oxidative stress in PC12 cells. Toxicol Lett 2004, 147: 63-72. 10.1016/j.toxlet.2003.10.023PubMedCrossRef
120.
go back to reference Domico LM, Zeevalk GD, Bernard LP, Cooper KR: Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are associated with mitochondrial dysfunction. Neurotoxicology 2006, 27: 816-825. 10.1016/j.neuro.2006.07.009PubMedCrossRef Domico LM, Zeevalk GD, Bernard LP, Cooper KR: Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are associated with mitochondrial dysfunction. Neurotoxicology 2006, 27: 816-825. 10.1016/j.neuro.2006.07.009PubMedCrossRef
121.
go back to reference Monnet-Tschudi F, Zurich MG, Pithon E, van Melle G, Honegger P: Microglial responsiveness as a sensitive marker for trimethyltin (TMT) neurotoxicity. Brain Res 1995, 690: 8-14. 10.1016/0006-8993(95)00509-OPubMedCrossRef Monnet-Tschudi F, Zurich MG, Pithon E, van Melle G, Honegger P: Microglial responsiveness as a sensitive marker for trimethyltin (TMT) neurotoxicity. Brain Res 1995, 690: 8-14. 10.1016/0006-8993(95)00509-OPubMedCrossRef
122.
go back to reference Monnet-Tschudi F, Zurich MG, Honegger P: Comparison of the developmental effects of two mercury compounds on glial cells and neurons in aggregate cultures of rat telencephalon. Brain Res 1996, 741: 52-59. 10.1016/S0006-8993(96)00895-5PubMedCrossRef Monnet-Tschudi F, Zurich MG, Honegger P: Comparison of the developmental effects of two mercury compounds on glial cells and neurons in aggregate cultures of rat telencephalon. Brain Res 1996, 741: 52-59. 10.1016/S0006-8993(96)00895-5PubMedCrossRef
123.
go back to reference Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989, 1: 1269.PubMedCrossRef Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989, 1: 1269.PubMedCrossRef
124.
go back to reference Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989, 26: 719-723. 10.1002/ana.410260606PubMedCrossRef Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989, 26: 719-723. 10.1002/ana.410260606PubMedCrossRef
125.
go back to reference Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW: Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol 1995, 37: 714-722. 10.1002/ana.410370604PubMedCrossRef Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW: Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol 1995, 37: 714-722. 10.1002/ana.410370604PubMedCrossRef
126.
go back to reference Rybakowska I, Szreder G, Kaletha K, Barwina M, Waldman W, Sein Anand J: [Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease]. Przegl Lek 2011, 68: 486-487.PubMed Rybakowska I, Szreder G, Kaletha K, Barwina M, Waldman W, Sein Anand J: [Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease]. Przegl Lek 2011, 68: 486-487.PubMed
127.
go back to reference Lee J, Giordano S, Zhang J: Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 2012, 441: 523-540. 10.1042/BJ20111451PubMedCentralPubMedCrossRef Lee J, Giordano S, Zhang J: Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 2012, 441: 523-540. 10.1042/BJ20111451PubMedCentralPubMedCrossRef
128.
go back to reference Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P: Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008, 14: 501-503. 10.1038/nm1746PubMedCrossRef Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P: Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008, 14: 501-503. 10.1038/nm1746PubMedCrossRef
129.
go back to reference Brundin P, Li JY, Holton JL, Lindvall O, Revesz T: Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008, 9: 741-745. 10.1038/nrn2477PubMedCrossRef Brundin P, Li JY, Holton JL, Lindvall O, Revesz T: Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008, 9: 741-745. 10.1038/nrn2477PubMedCrossRef
130.
go back to reference Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009, 106: 13010-13015. 10.1073/pnas.0903691106PubMedCentralPubMedCrossRef Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009, 106: 13010-13015. 10.1073/pnas.0903691106PubMedCentralPubMedCrossRef
131.
go back to reference Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM: Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011, 42: 360-367. 10.1016/j.nbd.2011.01.029PubMedCentralPubMedCrossRef Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM: Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011, 42: 360-367. 10.1016/j.nbd.2011.01.029PubMedCentralPubMedCrossRef
132.
go back to reference McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38: 1285-1291. 10.1212/WNL.38.8.1285PubMedCrossRef McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38: 1285-1291. 10.1212/WNL.38.8.1285PubMedCrossRef
133.
go back to reference McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):S3-S7.PubMedCrossRef McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):S3-S7.PubMedCrossRef
134.
go back to reference Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994, 172: 151-154. 10.1016/0304-3940(94)90684-XPubMedCrossRef Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994, 172: 151-154. 10.1016/0304-3940(94)90684-XPubMedCrossRef
135.
go back to reference Hunot S, Hirsch EC: Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003, 53(Suppl 3):S49-S58. discussion S58-60PubMedCrossRef Hunot S, Hirsch EC: Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003, 53(Suppl 3):S49-S58. discussion S58-60PubMedCrossRef
136.
go back to reference Gao HM, Hong JS, Zhang W, Liu B: Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 2003, 23: 1228-1236.PubMed Gao HM, Hong JS, Zhang W, Liu B: Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 2003, 23: 1228-1236.PubMed
137.
go back to reference Kohbata S, Beaman BL: L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 1991, 59: 181-191.PubMedCentralPubMed Kohbata S, Beaman BL: L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 1991, 59: 181-191.PubMedCentralPubMed
138.
go back to reference Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 2002, 81: 1285-1297. 10.1046/j.1471-4159.2002.00928.xPubMedCrossRef Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 2002, 81: 1285-1297. 10.1046/j.1471-4159.2002.00928.xPubMedCrossRef
139.
go back to reference Dutta G, Zhang P, Liu B: The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008, 22: 453-464. 10.1111/j.1472-8206.2008.00616.xPubMedCentralPubMedCrossRef Dutta G, Zhang P, Liu B: The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008, 22: 453-464. 10.1111/j.1472-8206.2008.00616.xPubMedCentralPubMedCrossRef
140.
go back to reference Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC: FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19: 3440-3447.PubMed Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC: FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19: 3440-3447.PubMed
141.
go back to reference Wong CH, Crack PJ: Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury. Curr Med Chem 2008, 15: 1-14. 10.2174/092986708783330665PubMedCrossRef Wong CH, Crack PJ: Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury. Curr Med Chem 2008, 15: 1-14. 10.2174/092986708783330665PubMedCrossRef
142.
go back to reference McGeer PL, McGeer EG: The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 2008, 212: 235-238. 10.1016/j.expneurol.2008.04.008PubMedCrossRef McGeer PL, McGeer EG: The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 2008, 212: 235-238. 10.1016/j.expneurol.2008.04.008PubMedCrossRef
143.
go back to reference Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS: Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 2011, 119: 807-814. 10.1289/ehp.1003013PubMedCentralPubMedCrossRef Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS: Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 2011, 119: 807-814. 10.1289/ehp.1003013PubMedCentralPubMedCrossRef
144.
go back to reference Esteves AR, Arduino DM, Silva DF, Oliveira CR, Cardoso SM: Mitochondrial dysfunction: The road to alpha-synuclein oligomerization in PD. Parkinsons Dis 2011, 2011: 693761.PubMedCentralPubMed Esteves AR, Arduino DM, Silva DF, Oliveira CR, Cardoso SM: Mitochondrial dysfunction: The road to alpha-synuclein oligomerization in PD. Parkinsons Dis 2011, 2011: 693761.PubMedCentralPubMed
145.
go back to reference Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O’Connor C, Wiethoff CM, Campbell EM: Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013, 8: e62143. 10.1371/journal.pone.0062143PubMedCentralPubMedCrossRef Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O’Connor C, Wiethoff CM, Campbell EM: Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013, 8: e62143. 10.1371/journal.pone.0062143PubMedCentralPubMedCrossRef
146.
go back to reference Chinta SJ, Mallajosyula JK, Rane A, Andersen JK: Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010, 486: 235-239. 10.1016/j.neulet.2010.09.061PubMedCentralPubMedCrossRef Chinta SJ, Mallajosyula JK, Rane A, Andersen JK: Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010, 486: 235-239. 10.1016/j.neulet.2010.09.061PubMedCentralPubMedCrossRef
147.
go back to reference Braidy N, Gai WP, Xu YH, Sachdev P, Guillemin GJ, Jiang XM, Ballard JW, Horan MP, Fang ZM, Chong BH, Chan DK: Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro. Neurotox Res 2014, 25: 170-182. 10.1007/s12640-013-9420-5PubMedCrossRef Braidy N, Gai WP, Xu YH, Sachdev P, Guillemin GJ, Jiang XM, Ballard JW, Horan MP, Fang ZM, Chong BH, Chan DK: Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro. Neurotox Res 2014, 25: 170-182. 10.1007/s12640-013-9420-5PubMedCrossRef
148.
go back to reference Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL: Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 2006, 20: 2000-2008. 10.1096/fj.06-6183comPubMedCrossRef Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL: Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 2006, 20: 2000-2008. 10.1096/fj.06-6183comPubMedCrossRef
149.
go back to reference Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM: Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28: 7687-7698. 10.1523/JNEUROSCI.0143-07.2008PubMedCentralPubMedCrossRef Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM: Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28: 7687-7698. 10.1523/JNEUROSCI.0143-07.2008PubMedCentralPubMedCrossRef
150.
go back to reference Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Trevino I, O’Brien DE, Casey B, Goldberg MS, Tansey MG: Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28: 10825-10834. 10.1523/JNEUROSCI.3001-08.2008PubMedCentralPubMedCrossRef Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Trevino I, O’Brien DE, Casey B, Goldberg MS, Tansey MG: Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28: 10825-10834. 10.1523/JNEUROSCI.3001-08.2008PubMedCentralPubMedCrossRef
151.
go back to reference Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM: Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007, 170: 658-666. 10.2353/ajpath.2007.060359PubMedCentralPubMedCrossRef Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM: Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007, 170: 658-666. 10.2353/ajpath.2007.060359PubMedCentralPubMedCrossRef
152.
go back to reference Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA: Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003, 23: 3095-3099.PubMed Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA: Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003, 23: 3095-3099.PubMed
153.
go back to reference Kahle PJ, Waak J, Gasser T: DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders. Free Radic Biol Med 2009, 47: 1354-1361. 10.1016/j.freeradbiomed.2009.08.003PubMedCrossRef Kahle PJ, Waak J, Gasser T: DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders. Free Radic Biol Med 2009, 47: 1354-1361. 10.1016/j.freeradbiomed.2009.08.003PubMedCrossRef
154.
go back to reference Masliah E, Dumaop W, Galasko D, Desplats P: Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 2013, 8: 1030-1038. 10.4161/epi.25865PubMedCentralPubMedCrossRef Masliah E, Dumaop W, Galasko D, Desplats P: Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 2013, 8: 1030-1038. 10.4161/epi.25865PubMedCentralPubMedCrossRef
155.
go back to reference Iacobazzi V, Castegna A, Infantino V, Andria G: Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol Genet Metab 2013, 110: 25-34. 10.1016/j.ymgme.2013.07.012PubMedCrossRef Iacobazzi V, Castegna A, Infantino V, Andria G: Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol Genet Metab 2013, 110: 25-34. 10.1016/j.ymgme.2013.07.012PubMedCrossRef
156.
go back to reference Marques S, Outeiro TF: Epigenetics in Parkinson’s and Alzheimer’s diseases. Sub-cellular biochemistry 2013, 61: 507-525. 10.1007/978-94-007-4525-4_22PubMedCrossRef Marques S, Outeiro TF: Epigenetics in Parkinson’s and Alzheimer’s diseases. Sub-cellular biochemistry 2013, 61: 507-525. 10.1007/978-94-007-4525-4_22PubMedCrossRef
157.
go back to reference Harrison IF, Dexter DT: Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson’s disease? Pharmacol Ther 2013, 140: 34-52. 10.1016/j.pharmthera.2013.05.010PubMedCrossRef Harrison IF, Dexter DT: Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson’s disease? Pharmacol Ther 2013, 140: 34-52. 10.1016/j.pharmthera.2013.05.010PubMedCrossRef
158.
go back to reference Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS: Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012, 485: 651-655. 10.1038/nature11060PubMedCentralPubMedCrossRef Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS: Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012, 485: 651-655. 10.1038/nature11060PubMedCentralPubMedCrossRef
Metadata
Title
Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology
Authors
Francisco Pan-Montojo
Heinz Reichmann
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2014
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/2047-9158-3-10

Other articles of this Issue 1/2014

Translational Neurodegeneration 1/2014 Go to the issue